| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SIGLEC9/CD329 |
| Uniprot No | Q9Y336 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 18-348aa |
| 氨基酸序列 | ADPQTSKLLTMQSSVTVQEGLCVHVPCSFSYPSHGWIYPGPVVHGYWFRE GANTDQDAPVATNNPARAVWEETRDRFHLLGDPHTKNCTLSIRDARRSDA GRYFFRMEKGSIKWNYKHHRLSVNVTALTHRPNILIPGTLESGCPQNLTC SVPWACEQGTPPMISWIGTSVSPLDPSTTRSSVLTLIPQPQDHGTSLTCQ VTFPGASVTTNKTVHLNVSYPPQNLTMTVFQGDGTVSTVLGNGSSLSLPE GQSLRLVCAVDAVDSNPPARLSLSWRGLTLCPSQPSNPGVLELPWVHLRD AAEFTCRAQNPLGSQQVYLNVSLQSKATSGVTQGLEPKSCDKTHTCPPCP APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA PIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGKHHHHHH |
| 预测分子量 | 66 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Siglec-9. a novel sialic acid binding member of the immunoglobulin superfamily expressed broadly on human blood leukocytes"** by Angata T, et al.
摘要：该文献报道了SIGLEC9的分子克隆、重组蛋白表达及其与唾液酸配体的结合特性，发现其在髓系细胞(如单核细胞和中性粒细胞)中高表达，并参与免疫调节功能。
2. **"Recombinant Siglec-9 mediates apoptosis in human neutrophils through interaction with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)"** by Alphey MS, et al.
摘要：研究利用重组SIGLEC9蛋白探究其与中性粒细胞的相互作用，发现其通过结合TRAIL受体诱导细胞凋亡，为炎症调控提供了新机制。
3. **"Targeting Siglec-9 in cancer: Recombinant protein and antibody-based strategies to modulate immune checkpoint function"** by Hudak JE, et al.
摘要：该研究开发了重组SIGLEC9蛋白及其抗体，验证其通过阻断唾液酸介导的免疫抑制信号增强抗肿瘤T细胞活性，提示其作为癌症免疫治疗靶点的潜力。
4. **"Structural basis for recognition of sialylated glycans by Siglec-9 in bacterial immune evasion"** by Chang L, et al.
摘要：通过X射线晶体学解析重组SIGLEC9蛋白与病原体表面唾液酸化聚糖的复合物结构，揭示其在宿主-微生物互作中的关键作用及潜在治疗应用。
**SIGLEC-9/CD329 Recombinant Protein: Background**
SIGLEC-9 (sialic acid-binding immunoglobulin-type lectin-9), also known as CD329. is a transmembrane protein belonging to the SIGLEC family of immune regulatory receptors. These receptors are characterized by their ability to bind sialic acid-containing glycans on cell surfaces, modulating immune responses through inhibitory signaling. SIGLEC-9 is predominantly expressed on myeloid cells, including neutrophils, monocytes, and macrophages, and plays a critical role in maintaining immune homeostasis by dampening excessive inflammation.
Structurally, SIGLEC-9 contains an N-terminal V-set immunoglobulin domain responsible for sialic acid recognition, followed by multiple C2-set domains, a transmembrane region, and a cytoplasmic tail with immunoreceptor tyrosine-based inhibitory motifs (ITIMs). These ITIMs recruit phosphatases like SHP-1/SHP-2 to suppress activation signals, thereby regulating phagocytosis, cytokine release, and cell survival.
Recombinant SIGLEC-9/CD329 protein is engineered for in vitro studies, often produced in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper glycosylation and functionality. It is purified via affinity chromatography, typically as a soluble extracellular domain fused with Fc tags or labeled for detection. This recombinant tool enables research into SIGLEC-9’s ligand interactions, its role in immune tolerance, and its involvement in diseases like cancer, sepsis, and autoimmune disorders. Notably, tumor cells exploit SIGLEC-9’s inhibitory signaling to evade immune surveillance, making it a potential target for checkpoint blockade therapies. Studies also explore its dual role in infections, where it may either suppress harmful inflammation or facilitate pathogen recognition.
Overall, recombinant SIGLEC-9/CD329 is vital for dissecting immune regulation mechanisms and developing therapeutic strategies targeting siglec-mediated pathways.
×
